A meta-analysis of 8 randomized controlled trials examined the effects of SGLT2 inhibitors on serious heart rhythm problems in patients with chronic kidney disease (CKD). The study compared SGLT2 inhibitors to placebo and looked at outcomes including cardiac arrest, ventricular arrhythmias, and atrioventricular block.
The results showed that SGLT2 inhibitors significantly reduced the risk of cardiac arrest by about 47%. In the treatment group, 0.12% of patients experienced cardiac arrest compared to 0.23% in the placebo group. This difference was statistically significant.
However, the medications did not significantly reduce the risk of other specific arrhythmias such as ventricular tachycardia, ventricular fibrillation, or atrioventricular block. The rates of these events were low in both groups, and the reductions seen were not statistically significant.
These findings suggest that while SGLT2 inhibitors may help prevent cardiac arrest in CKD patients, they do not appear to protect against other types of dangerous heart rhythm disturbances. The study provides reassurance about the safety of these medications regarding arrhythmias.
Further research is needed to understand why SGLT2 inhibitors reduce cardiac arrest risk without affecting other arrhythmias. Patients with CKD should discuss the potential benefits and risks of SGLT2 inhibitors with their healthcare provider.